熱門資訊> 正文
Elanco因FDA批准Zenrelia而上涨
2024-09-20 00:57
- Shares of Elanco Animal Health (NYSE:ELAN) reached a session high on Thursday after the U.S. Food and Drug Administration (FDA) approved the veterinary product maker’s JAK inhibitor Zenrelia for dogs.
- According to the regulator’s labeling information, Zenrelia tablets will be indicated in the U.S. to control pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs aged at least 12 months.
- In June, Elanco (ELAN) revised the timeline for the U.S. commercial rollout of Zenrelia to Q4 2024 from Q3 2024, expecting a potential FDA approval for the drug in Q3.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
